Brainstorm Cell Therapeutics Total Revenue

Brainstorm Cell Therapeutics (BCLI) currently reports a total revenue of $880K as of June 2026. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $11T. Use the charts on this page to explore Brainstorm Cell Therapeutics's total revenue history and peer comparisons.

Brainstorm Cell Therapeutics's total revenue changed from $0 to $880K (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brainstorm Cell Therapeutics's total revenue of $880K is lower than the Healthcare sector average of $11T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Brainstorm Cell Therapeutics reported $880K in total revenue as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $880K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $11T. From there, open related valuation or income-statement pages for Brainstorm Cell Therapeutics, and consider following BCLI for alerts when major investors trade the stock.